STZ

Constellation Brands Inc

Stocks

Here Are Three Reasons Why The New York Times Is Dead Wrong About Cannabis

by

Last week, The New York Times ran an editorial piece with the headline, "Do We Really Want a Microsoft of Marijuana?"

The author of the report, Christopher Caldwell, opines that the SAFE Banking Act would disproportionately help giant operators at the expense of smaller companies. That, in turn, would usher in a dystopian future in which multinational businesses develop new flavors and products to turn America's children into a nation of potheads.

I read a lot of wrongheaded news and misinformation pieces about cannabis, but this one may be the winner in terms of getting things wrong.

In barely 1,000 words, the author makes three points that need addressing.

The first is the overall theme. We absolutely want a Microsoft of marijuana!

We want one as investors, as consumers, and as supporters of the industry. Microsoft has its flaws, but overall, a lot of people have benefited from the success of the tech company. We can partially thank Microsoft for reliable computer operating systems, sophisticated spreadsheets, and cheap cloud computing that allows us to share our ideas in real time all over the world.

Do we want a company with the resources to improve the accuracy and speed of cannabis testing, one that can grow more precise strains for medical patients, and one that can perfect security and seed-to-sale tracking?

I want those things. So do you.

And he doesn't know it yet, but so does Mr. Caldwell. Here's why… Full Story

And he doesn't know it yet, but so does Mr. Caldwell. Here's why... Full Story

What Every Investor Should Know About Canopy Right Now

by

Canopy Growth disappointed investors with its quarterly earnings. In fact, investors were so "disappointed" by this one report they sent the entire cannabis sector tumbling.

That's the thing: Canopy's results mean essentially nothing at all for American marijuana companies – nothing for any company outside Canada, in fact.

It's no different than if, say, California-based PG&E shares tanked because Consolidated Edison had a power failure in New York City.

But we're still in the early stages of legal cannabis' explosive growth potential.

Canopy led the sector down because investors are expecting results yesterday. And the results can be longer in coming than short-sighted investors might like.

So before you run out and sell all your Canopy shares, you need to see what I'm about to show you...

Stocks

Why Constellation Brands Is Still a Company You'll Want to Own Forever

by

Back in early July, I told my readers that one of the "safer" ways to invest in Canopy Growth was through buying shares of Constellation Brands.

Constellation owns a 38% stake in Canopy, so it has skin in the game and exposure to the cannabis market.

But that's just scratching the surface…

Outside of its stake in Canopy, which is already a huge deal, Constellation is also the maker of Corona and owns whiskey, vodka, and tequila brands. This gives it yet another source of revenue and a defensive moat.

Bottom line, it's truly a force to be reckoned with in the cannabis sector!

However, Constellation is already looking ahead to the future. It has sold off some of its wine brands that retail for under $11 so that management can focus on selling more lucrative adult beverages.

Overall, I believe that this is a stock you can retire on. Why? Constellation is a powerhouse company you'll want to keep in your portfolio on a very long-term basis – because it's only going to grow every year.

With that kind of growth and profit potential, you'll be living a very comfortable retirement.

Now, the stock price did take a bit of a dip in January, but it's been rebounding ever since. And you shouldn't be listening to those newer investors who like to focus on the share price and say it's expensive. If you focus on accumulating shares of a quality company, it will add up over time.

Plus, by offering something most cannabis companies can’t right now, it’s doubling its enormous profit potential…

Stocks

The Market Just Put One of the Best Cannabis Stocks on Sale

by

This week, an 800-point drop in the Dow Jones Industrial Average caused investor fears to spike.

But this has actually created a great opportunity to pick up shares of one of the best cannabis stocks to buy.

We do not think the bull market is over.

Corrections are supposed to happen from time to time, and they provide buying opportunities.

But here’s where it got even better for us…

Earnings

Here's What's Really Happening with Aphria's Stellar Earnings Report

by

Aphria reported its fiscal fourth-quarter earnings last week, and the company exceeded all expectations.

And it beat those estimates from underneath a cloud of short sellers' spurious innuendo, to boot.

After a quarter of overall decline in Canadian cannabis revenue, Aphria saw an increase of 85% – that's 85% sequentially and not year over year. The company also turned earnings before interest, tax, depreciation, and amortization (EBITDA) positive – albeit after adjustments and with help from a European pharmaceutical distribution business the company owns.

And to top it off, management's optimistic about the future.

So any investor could look at Aphria's reporting and conclude it had a great quarter. And they'd be dead on.

What might not be so obvious at first glance is that this company just showed investors how it was going to take the cannabis sector to the next level.

There’s much more here than meets the eye…

Stocks

You'll Want to Own Canopy Growth Forever, so Here Are Three Ways to Profit from It

by

Our Greg Miller’s bringing you the latest update on Canopy Growth following CEO Bruce Linton’s firing last week.

Not only is a shakeup in management common in startup companies, but it’s actually welcome so that the firm can reach its next level of success.

In fact, Greg’s going to show you three ways you can reap the most profits from this stock that you’ll want to keep in your portfolio for a long time…

Read more...